Verify patient identity and site of injection. Review medical history for contraindications including active local or systemic infection, coagulopathy, or allergy to corticosteroids/anesthetics. Obtain informed consent. Position the patient comfortably in the lateral decubitus position with the affected side up.
Monitor the patient for immediate adverse reactions for 15 minutes. Advise the patient to avoid strenuous physical activity or weight-bearing exercise on the affected hip for 48 hours. Use ice packs for local discomfort. Resume routine activities as tolerated after 48 hours. Follow up if symptoms persist or if signs of infection occur.
Comprehensive Guide: Trochanteric Bursa Injection (Corticosteroid)
1. Introduction & Overview
Greater Trochanteric Pain Syndrome (GTPS) represents a constellation of clinical findings characterized by lateral hip pain, often exacerbated by pressure, prolonged standing, or climbing stairs. At the epicenter of this pathology is the trochanteric bursa—a fluid-filled sac designed to reduce friction between the tendons of the gluteus medius/minimus and the prominence of the greater trochanter.
When this bursa becomes inflamed (bursitis), the resulting pain can be debilitating. A corticosteroid injection into the trochanteric bursa serves as both a diagnostic and therapeutic intervention. By delivering a potent anti-inflammatory agent directly to the site of inflammation, clinicians can effectively break the cycle of pain, facilitate physical therapy, and restore functional mobility. This guide provides an exhaustive clinical overview for medical practitioners and patients seeking a deep understanding of the procedure.
2. Technical Specifications & Mechanisms
The Anatomy of the Greater Trochanter
The greater trochanter serves as the attachment site for several hip abductor muscles. The trochanteric bursa is situated between the lateral aspect of the greater trochanter and the overlying iliotibial (IT) band and gluteus maximus tendon. Chronic friction or repetitive micro-trauma often leads to thickening of the bursa and localized fluid accumulation.
Mechanism of Action: Corticosteroids
Corticosteroids (e.g., Triamcinolone acetonide, Methylprednisolone acetate) are potent synthetic analogs of cortisol. Their therapeutic efficacy in bursitis is derived from:
* Inhibition of Phospholipase A2: This prevents the release of arachidonic acid, effectively blocking the production of prostaglandins and leukotrienes.
* Downregulation of Cytokines: Suppression of pro-inflammatory cytokines such as IL-1 and TNF-alpha.
* Stabilization of Lysosomal Membranes: Reducing the release of destructive enzymes into the surrounding tissue.
Pharmacological Selection
| Agent | Typical Dosage | Onset of Action | Duration of Effect |
|---|---|---|---|
| Triamcinolone Acetonide | 20–40 mg | 2–5 days | 4–12 weeks |
| Methylprednisolone Acetate | 40–80 mg | 3–7 days | 4–8 weeks |
| Dexamethasone | 4–8 mg | Rapid (24h) | Short-term |
3. Clinical Indications & Usage
Indications for Intervention
A corticosteroid injection is indicated when conservative management—including rest, non-steroidal anti-inflammatory drugs (NSAIDs), and physical therapy—has failed to provide relief after 4–6 weeks.
- Diagnosis of GTPS: Confirmation of lateral hip pain localized to the trochanteric prominence.
- Refractory Bursitis: Failure of conservative protocols.
- Acute Flare-ups: Severe inflammation preventing the initiation of rehabilitative exercises.
- Diagnostic Confirmation: If pain resolves completely post-injection, it confirms the bursa as the primary pain generator, helping to rule out referred lumbar spine pain or intra-articular hip pathology.
Patient Selection Criteria
- Patients with localized tenderness over the greater trochanter.
- Positive "jump sign" or pain on resisted hip abduction.
- Absence of localized skin infection or systemic sepsis.
- Absence of uncontrolled coagulopathy.
4. The Procedure: Step-by-Step
Pre-Procedure Preparation
- Informed Consent: Discuss risks (infection, fat atrophy, skin depigmentation) and expected outcomes.
- Positioning: Patient should be in a lateral decubitus position (painful side up) or standing, leaning forward to expose the trochanter.
- Sterilization: Use an aseptic technique with chlorhexidine or povidone-iodine.
- Imaging Guidance: While anatomical landmarks (the "point of maximum tenderness") are often sufficient, ultrasound-guided injection is the gold standard to ensure precise placement and avoid inadvertent injection into the gluteal tendons.
Procedural Steps
- Identification: Palpate the greater trochanteric prominence. If using ultrasound, identify the hypoechoic bursa between the bone and the IT band.
- Anesthesia: Use a small gauge needle (25G or 27G) to create a local wheal of 1% Lidocaine or Bupivacaine at the entry site.
- Needle Placement: Advance a 22G or 25G needle until it contacts the bone, then withdraw slightly (1-2mm) to ensure the tip is within the bursal space.
- Aspiration: Attempt to aspirate; if fluid is present, send for analysis if infection is suspected.
- Injection: Slowly inject the corticosteroid/anesthetic mixture. Resistance indicates improper placement (e.g., intra-tendinous).
- Post-Injection: Apply pressure and a sterile dressing.
5. Post-Op Recovery & Rehabilitation
Post-procedural care is as critical as the injection itself. The goal is to transition from pain relief to functional restoration.
- Immediate (0–48 hours): Relative rest. Avoid high-impact activities. Ice the area for 15 minutes every 4 hours to manage post-injection soreness.
- The "Steroid Flare": Patients should be warned of a temporary increase in pain (24–48 hours) as the crystal suspension settles in the tissue.
- Rehabilitation (Days 3–14): Begin gentle hip abductor strengthening. Avoid aggressive stretching of the IT band, which can exacerbate friction.
- Long-term: Focus on pelvic stability, core strengthening, and biomechanical correction (gait analysis).
6. Risks, Side Effects, and Contraindications
Risks and Complications
- Post-Injection Flare: Occurs in 10-20% of patients.
- Subcutaneous Fat Atrophy: A localized dimpling of the skin due to corticosteroid-induced suppression of fibroblasts.
- Skin Depigmentation: Especially in darker skin tones; usually reversible over 6–12 months.
- Infection (Septic Bursitis): Rare (<0.1%) but serious. Requires immediate antibiotic intervention.
- Tendon Rupture: Risk associated with repetitive injections directly into the gluteal tendon (avoid by using ultrasound guidance).
Contraindications
- Absolute: Known allergy to the steroid or local anesthetic; active local infection; cellulitis.
- Relative: Uncontrolled diabetes (steroids may cause transient hyperglycemia); pregnancy (weigh risks vs. benefits); use of anticoagulants (unless managed appropriately).
7. Alternative Treatments
When injections provide only temporary relief or are contraindicated, consider:
* Platelet-Rich Plasma (PRP): Using autologous growth factors to stimulate tissue healing rather than merely suppressing inflammation.
* Extracorporeal Shockwave Therapy (ESWT): Stimulates a healing response in chronic, fibrotic tendinopathy.
* Surgical Bursectomy: Reserved for recalcitrant cases; involves the endoscopic or open removal of the bursa and release of the IT band.
* Physical Therapy (Focused): Emphasis on gluteus medius strengthening and correcting "Trendelenburg" gait patterns.
8. Frequently Asked Questions (FAQ)
1. How long does it take for the injection to work?
Most patients feel the anesthetic effect immediately. The corticosteroid effect typically begins 2–5 days post-procedure.
2. Can I drive after the procedure?
Yes, you can typically drive, though some patients prefer a ride home if their hip was significantly painful prior to the procedure.
3. How many injections can I have?
Generally, no more than 3 injections per year into the same site to avoid long-term tissue degradation.
4. Is the procedure painful?
The initial needle stick is similar to a blood draw. The injection itself may cause pressure or a dull ache.
5. What if the pain returns after a few weeks?
This suggests the primary issue is mechanical (e.g., muscle weakness or gait abnormality) rather than purely inflammatory. Further physical therapy is recommended.
6. Will this injection cure my hip pain permanently?
It treats the inflammation, not the cause. Without physical therapy to address the underlying mechanics, the pain may return.
7. Does the injection contain anything else?
It is usually a mixture of a corticosteroid (e.g., Triamcinolone) and a local anesthetic (e.g., Lidocaine) to provide immediate diagnostic feedback.
8. What is the success rate?
Most literature suggests a 60–80% success rate in providing significant symptom relief for at least 3 months.
9. Can I take NSAIDs after the injection?
Yes, NSAIDs can be used safely in conjunction with the injection to manage post-procedural soreness.
10. Are there any restrictions on my activities after the injection?
Avoid high-impact activities (running, jumping) for at least 48–72 hours to allow the medication to localize and settle.
9. Conclusion
The trochanteric bursa injection remains a cornerstone of orthopedic non-operative management. By leveraging precise anatomical knowledge and, where possible, ultrasound guidance, clinicians can provide rapid relief to patients suffering from GTPS. However, the procedure must be viewed as a gateway to rehabilitation rather than a standalone cure. Long-term success is predicated on a comprehensive approach that includes biomechanical assessment and targeted strengthening of the hip abductor complex. As with all medical interventions, patient education remains the most potent tool in ensuring adherence to the recovery protocol and managing realistic expectations.
